Answers are grounded in this paper and cite their sources.
Evaluates local therapy effects on outcomes in metastatic breast cancer, suggesting curative potential.
Metastatic breast cancer (MBC) management is based on systemic treatment (ST), while the local therapy role remains controversial. We present the case of a 36-year-old woman with a diagnosis of hormone receptor-positive and human epidermal growth factor receptor type 2-positive breast cancer and isolated sternal metastasis, who received neoadjuvant ST with complete remission and later primary tumour surgery. Oligometastatic patients are a subgroup of MBC that can benefit from aggressive local therapies, even with curative intent.
No takes yet. Share an insight, caveat, or question.
Vargas et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: